Omnicell, Inc. (OMCL) Soars to 52-Week High, Time to Cash Out?
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Omnicell, Inc. (OMCL) Q3 2024 Earnings Call Transcript
Omnicell, Inc. (NASDAQ:OMCL ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Kathleen Neiman - Senior Vice President, Investor Relations Randall Lipps - Founder, Chairman, President & Chief Executive Officer Nchacha Etta - Executive Vice President & Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Jessica Tassan - Piper Sandler Allen Lutz - Bank of America Stephanie Davis - Barclays Anne Samuel - JPMorgan Scott Schoenhaus - KeyBanc Capital Markets Bill Sutherland - The Benchmark Company Stan Berenshteyn - Wells Fargo David Larsen - BTIG Operator Thank you for standing by. My name is John, and I'll be your conference operator today.
Omnicell (OMCL) Beats Q3 Earnings and Revenue Estimates
Omnicell (OMCL) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.62 per share a year ago.
Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell
Medical Systems, 10x Genomics and Omnicell have been highlighted in this Industry Outlook article.
Omnicell: Innovating Medication Management and Driving Growth in the Healthcare Sector
In this ROBO Global Robotics and Automation Index spotlight, we focus on Omnicell Inc (OMCL). The index underlies the $1.13 billion ROBO Global Robotics and Automation ETF (ROBO).
Omnicell (OMCL) Moves to Strong Buy: Rationale Behind the Upgrade
Omnicell (OMCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for October 4th
OMCL and SFBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 4, 2024.
Should You Continue to Retain OMCL Stock in Your Portfolio Now?
Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.
Earnings Estimates Moving Higher for Omnicell (OMCL): Time to Buy?
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Omnicell (OMCL) Introduces Central Med Automation Service
Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.
Omnicell, Inc. (OMCL) Q2 2024 Earnings Call Transcript
Omnicell, Inc. (NASDAQ:OMCL ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President Randall Lipps - Founder, Chairman, President and CEO Nchacha Etta - Executive Vice President and CFO Conference Call Participants Stan Berenshteyn - Wells Fargo Scott Schoenhaus - KeyBanc Matt Hewitt - Craig-Hallum Capital Group David Larsen - BTIG Bill Sutherland - The Benchmark Company Anna Kruszenski - Barclays Allen Lutz - Bank of America Jessica Tassan - Piper Sandler Anne Samuel - JPMorgan Operator Good morning and thank you for standing by. My name is Aaron, and I will be your conference operator for today.
Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down
Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.
